News & Updates

Placing awake COVID-19 patients with acute hypoxaemic respiratory failure (AHRF) in a prone position is an efficacious intervention in terms of both reducing mortality and preventing intubation, according to an individual participant data meta-analysis.

Antibiotic treatment may be done for 5 days, as opposed to at least 7 days, in hospitalized patients with community-acquired pneumonia (CAP) who had achieved clinical stability by day 3 to 5, suggests a study presented at ESCMID Global 2025.

Updated data from the EPIC-HR* trial show reduced duration of COVID-19 symptoms and utilization of healthcare resources with nirmatrelvir/ritonavir (NMV/r) in high-risk, unvaccinated, nonhospitalized, symptomatic adults with COVID-19.

In adults who have survived the COVID-19 pandemic, health-related quality of life (HRQoL) is high among those who had either recovered from post-COVID-19 condition (PCC) or had never been afflicted with PCC, according to a study.

Treatment with monoclonal antibodies (mAbs) among COVID-19 patients is associated with a higher risk of hepatotoxicity and neutropenia when compared with standard of care (SoC) or placebo, reports a study.